ArticleTissue barriers2025
Therapeutic effects of selenium nanoparticles versus selenium on experimentally induced diabetic retinopathy via modulation of TLR4 / NF-
Article in Tissue barriers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- CanInternational journal of molecular sciences · 2026Article
- Nanomaterial-enabled delivery of plant-derived bioactive metabolites for diabetic retinopathy: from evidence appraisal to preclinical translation.Frontiers in pharmacology · 2026Review
- Natural antioxidant products and nanomaterial-based delivery systems for the amelioration of diabetic retinopathy: mechanisms, applications, and translational perspectives.Frontiers in immunology · 2026Review
- Recent Progress in Selenium Nanomedicines for Ocular Diseases.International journal of nanomedicine · 2026Review
- Exploring Molecular Signatures Associated with Inflammation and Angiogenesis in the Aqueous Humor of Patients with Non-Proliferative Diabetic Retinopathy.International journal of molecular sciences · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic retinopathy is the most prevalent microvascular consequences of diabetes mellitus that can result in vision loss. Nanotechnology has been widely used in the treatment of ophthalmic diseases. Selenium is a naturally occurring compound that has antioxidant and anti-inflammatory effects. This study aimed at comparing the possible ameliorating effect of selenium versus Nano-selenium on streptozotocin-induced diabetic retinopathy in rats. Sixty adult male albino-Wister rats were divided randomly into six groups; control, Selenium+ve, Nanoselenium+ve, diabetic, DR-Se treated group, and DR-NS treated group. Animals were anesthetized and sacrificed at the end of study. Eyes were removed and prepared for biochemical, histological, and immunohistochemical studies. The results showed that the diabetic group had an apparent decrease in retinal thickness, loss of photoreceptors, dilated congested blood vessels in retinal layers. Additionally, a significant increase in malondialdehyde and significant decrease in Total Antioxidant Capacity were detected. Significant increase in surface area fraction of vascular endothelial growth factor, nuclear factor kappa B, Glial fibrillary acidic protein immune stained cells were noticed, and significant decrease in connexin 43 expression was also detected. Improvement in all mentioned parameters in DR-Se and DR-NS groups was noticed. Our study suggested that Selenium, whether in its regular or nano form, holds promise for alleviating diabetic retinopathy in rats on biochemical, histological, and immunohistochemical basis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.